Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 503.6m

Basilea Pharmaceutica Valuation

Is BSLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BSLN (CHF41.65) is trading below our estimate of fair value (CHF44.52)

Significantly Below Fair Value: BSLN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSLN?

Key metric: As BSLN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BSLN. This is calculated by dividing BSLN's market cap by their current revenue.
What is BSLN's PS Ratio?
PS Ratio3.4x
SalesCHF 149.02m
Market CapCHF 503.63m

Price to Sales Ratio vs Peers

How does BSLN's PS Ratio compare to its peers?

The above table shows the PS ratio for BSLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.4x
IDIA Idorsia
3.3x36.0%CHF 244.1m
KURN Kuros Biosciences
14.7xn/aCHF 770.2m
MOLN Molecular Partners
29.7x57.9%CHF 178.0m
RLF Relief Therapeutics Holding
6xn/aCHF 51.4m
BSLN Basilea Pharmaceutica
3.4x5.9%CHF 504.8m

Price-To-Sales vs Peers: BSLN is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (13.4x).

Price to Sales Ratio vs Industry

How does BSLN's PS Ratio compare vs other companies in the European Biotechs Industry?

40 CompaniesPrice / SalesEstimated GrowthMarket Cap
BSLN 3.4xIndustry Avg. 8.1xNo. of Companies40PS0816243240+
40 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BSLN is good value based on its Price-To-Sales Ratio (3.4x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is BSLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.4x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: BSLN is expensive based on its Price-To-Sales Ratio (3.4x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 41.65
CHF 77.25
+85.5%
31.6%CHF 120.00CHF 52.00n/a6
Dec ’25CHF 41.70
CHF 77.25
+85.3%
31.6%CHF 120.00CHF 52.00n/a6
Nov ’25CHF 43.20
CHF 74.87
+73.3%
35.7%CHF 120.00CHF 44.20n/a6
Oct ’25CHF 45.60
CHF 73.20
+60.5%
32.8%CHF 110.00CHF 44.20n/a6
Sep ’25CHF 46.00
CHF 72.37
+57.3%
32.0%CHF 110.00CHF 44.20n/a6
Aug ’25CHF 39.75
CHF 71.20
+79.1%
30.5%CHF 105.00CHF 44.20n/a6
Jul ’25CHF 39.50
CHF 71.20
+80.3%
30.5%CHF 105.00CHF 44.20n/a6
Jun ’25CHF 43.70
CHF 70.58
+61.5%
31.9%CHF 105.00CHF 40.50n/a6
May ’25CHF 39.50
CHF 70.58
+78.7%
31.9%CHF 105.00CHF 40.50n/a6
Apr ’25CHF 37.65
CHF 69.08
+83.5%
30.6%CHF 105.00CHF 40.50n/a6
Mar ’25CHF 35.15
CHF 69.08
+96.5%
30.6%CHF 105.00CHF 40.50n/a6
Feb ’25CHF 33.05
CHF 64.38
+94.8%
24.7%CHF 85.00CHF 40.50n/a4
Jan ’25CHF 35.30
CHF 70.70
+100.3%
26.5%CHF 91.00CHF 40.50n/a5
Dec ’24CHF 34.95
CHF 75.68
+116.5%
19.8%CHF 91.00CHF 57.70CHF 41.704
Nov ’24CHF 35.60
CHF 73.28
+105.9%
20.1%CHF 91.00CHF 52.00CHF 43.206
Oct ’24CHF 41.00
CHF 70.44
+71.8%
21.7%CHF 91.00CHF 52.00CHF 45.607
Sep ’24CHF 48.20
CHF 70.44
+46.1%
21.7%CHF 91.00CHF 52.00CHF 46.007
Aug ’24CHF 43.85
CHF 70.44
+60.6%
21.7%CHF 91.00CHF 52.00CHF 39.757
Jul ’24CHF 42.25
CHF 67.18
+59.0%
21.0%CHF 91.00CHF 52.00CHF 39.506
Jun ’24CHF 45.90
CHF 67.18
+46.4%
21.0%CHF 91.00CHF 52.00CHF 43.706
May ’24CHF 43.20
CHF 72.07
+66.8%
20.8%CHF 91.00CHF 52.00CHF 39.506
Apr ’24CHF 50.10
CHF 74.80
+49.3%
18.4%CHF 91.00CHF 52.00CHF 37.655
Mar ’24CHF 52.40
CHF 68.98
+31.6%
26.2%CHF 91.00CHF 39.90CHF 35.156
Feb ’24CHF 49.00
CHF 73.82
+50.6%
34.7%CHF 120.00CHF 39.90CHF 33.056
Jan ’24CHF 45.80
CHF 69.15
+51.0%
26.2%CHF 91.00CHF 39.90CHF 35.306
Dec ’23CHF 49.75
CHF 68.58
+37.8%
28.9%CHF 91.00CHF 39.90CHF 34.955

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 19:20
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Basilea Pharmaceutica AG is covered by 26 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research